Intake Patterns of Specific Alcoholic Beverages by Prostate Cancer Status.

aggressiveness alcohol beverage prostate cancer

Journal

Cancers
ISSN: 2072-6694
Titre abrégé: Cancers (Basel)
Pays: Switzerland
ID NLM: 101526829

Informations de publication

Date de publication:
14 Apr 2022
Historique:
received: 04 03 2022
revised: 03 04 2022
accepted: 07 04 2022
entrez: 23 4 2022
pubmed: 24 4 2022
medline: 24 4 2022
Statut: epublish

Résumé

Previous studies have shown that different alcoholic beverage types impact prostate cancer (PCa) clinical outcomes differently. However, intake patterns of specific alcoholic beverages for PCa status are understudied. The study's objective is to evaluate intake patterns of total alcohol and the three types of beverage (beer, wine, and spirits) by the PCa risk and aggressiveness status. This is a cross-sectional study using 10,029 men (4676 non-PCa men and 5353 PCa patients) with European ancestry from the PCa consortium. Associations between PCa status and alcohol intake patterns (infrequent, light/moderate, and heavy) were tested using multinomial logistic regressions. Intake frequency patterns of total alcohol were similar for non-PCa men and PCa patients after adjusting for demographic and other factors. However, PCa patients were more likely to drink wine (light/moderate, OR = 1.11, The intake patterns of some alcoholic beverage types differed by PCa status. Our findings can provide valuable information for developing custom alcohol interventions for PCa patients.

Sections du résumé

BACKGROUND BACKGROUND
Previous studies have shown that different alcoholic beverage types impact prostate cancer (PCa) clinical outcomes differently. However, intake patterns of specific alcoholic beverages for PCa status are understudied. The study's objective is to evaluate intake patterns of total alcohol and the three types of beverage (beer, wine, and spirits) by the PCa risk and aggressiveness status.
METHOD METHODS
This is a cross-sectional study using 10,029 men (4676 non-PCa men and 5353 PCa patients) with European ancestry from the PCa consortium. Associations between PCa status and alcohol intake patterns (infrequent, light/moderate, and heavy) were tested using multinomial logistic regressions.
RESULTS RESULTS
Intake frequency patterns of total alcohol were similar for non-PCa men and PCa patients after adjusting for demographic and other factors. However, PCa patients were more likely to drink wine (light/moderate, OR = 1.11,
CONCLUSIONS CONCLUSIONS
The intake patterns of some alcoholic beverage types differed by PCa status. Our findings can provide valuable information for developing custom alcohol interventions for PCa patients.

Identifiants

pubmed: 35454886
pii: cancers14081981
doi: 10.3390/cancers14081981
pmc: PMC9024489
pii:
doi:

Types de publication

Journal Article

Langues

eng

Subventions

Organisme : NCI NIH HHS
ID : U01 CA182883
Pays : United States
Organisme : NCI NIH HHS
ID : UG1 CA189974
Pays : United States

Références

Cancer Causes Control. 2005 Apr;16(3):275-84
pubmed: 15947879
Prostate. 1998 Sep 1;36(4):250-5
pubmed: 9719025
J Registry Manag. 2013 Winter;40(4):159-64
pubmed: 24625768
J Clin Oncol. 2019 Jun 10;37(17):1499-1511
pubmed: 31026211
J Adv Pract Oncol. 2016 May-Jun;7(4):422-433
pubmed: 29226000
Am J Epidemiol. 2010 Oct 1;172(7):773-80
pubmed: 20813803
J Natl Compr Canc Netw. 2020 Jan;18(1):69-79
pubmed: 31910381
Genet Epidemiol. 2016 Jul;40(5):356-65
pubmed: 27061572
Clin Psychol Rev. 2004 Dec;24(8):981-1010
pubmed: 15533281
Nat Genet. 2018 Jul;50(7):928-936
pubmed: 29892016
Transl Cancer Res. 2019 Jan;8(Suppl 4):S334-S345
pubmed: 31497514
Cancer Epidemiol. 2016 Dec;45:11-17
pubmed: 27664387
Br J Cancer. 2015 Feb 3;112(3):580-93
pubmed: 25422909
Cancer Epidemiol Biomarkers Prev. 2008 May;17(5):1282-7
pubmed: 18483352
Nutrients. 2020 Jul 23;12(8):
pubmed: 32717903
BMC Cancer. 2016 Nov 15;16(1):845
pubmed: 27842506
Alcohol Res. 2013;35(2):155-73
pubmed: 24881324
Prostate Cancer Prostatic Dis. 2017 Sep;20(3):305-310
pubmed: 28417982
Crit Rev Food Sci Nutr. 2019;59(4):676-692
pubmed: 28980828
Nutr Cancer. 2021;73(11-12):2538-2545
pubmed: 33148052
CA Cancer J Clin. 2021 May;71(3):209-249
pubmed: 33538338
Nutrition. 2016 Jul-Aug;32(7-8):799-805
pubmed: 27138106
Cancer Epidemiol. 2021 Dec;75:102054
pubmed: 34773768

Auteurs

Hui-Yi Lin (HY)

Biostatistics Program, School of Public Health, Louisiana State University Health Sciences Center, New Orleans, LA 70112, USA.

Tung-Sung Tseng (TS)

Behavioral and Community Health Sciences Program, School of Public Health, Louisiana State University Health Sciences Center, New Orleans, LA 70112, USA.

Xinnan Wang (X)

Biostatistics Program, School of Public Health, Louisiana State University Health Sciences Center, New Orleans, LA 70112, USA.

Zhide Fang (Z)

Biostatistics Program, School of Public Health, Louisiana State University Health Sciences Center, New Orleans, LA 70112, USA.

Arnold H Zea (AH)

Department of Microbiology, School of Medicine, Louisiana State University Health Sciences Center, New Orleans, LA 70112, USA.
Stanley S. Scott Cancer Center, Louisiana State University Health Sciences Center, New Orleans, LA 70112, USA.

Liang Wang (L)

Department of Tumor Biology, Moffitt Cancer Center & Research Institute, Tampa, FL 33612, USA.

Julio Pow-Sang (J)

Department of Genitourinary Oncology, Moffitt Cancer Center & Research Institute, Tampa, FL 33612, USA.

Catherine M Tangen (CM)

SWOG Statistical Center, Fred Hutchinson Cancer Research Center, Seattle, WA 98109, USA.

Phyllis J Goodman (PJ)

SWOG Statistical Center, Fred Hutchinson Cancer Research Center, Seattle, WA 98109, USA.

Alicja Wolk (A)

Department of Surgical Sciences, Uppsala University, SE-751 85 Uppsala, Sweden.

Niclas Håkansson (N)

Unit of Cardiovascular and Nutritional Epidemiology, Institute of Environmental Medicine, Karolinska Institutet, SE-171 77 Stockholm, Sweden.

Manolis Kogevinas (M)

Barcelona Institute of Global Health (ISGlobal), 08036 Barcelona, Spain.
IMIM (Hospital del Mar Medical Research Institute), 08003 Barcelona, Spain.
Universitat Pompeu Fabra (UPF), 08002 Barcelona, Spain.
CIBER Epidemiología y Salud Pública (CIBERESP), 28029 Madrid, Spain.

Javier Llorca (J)

CIBER Epidemiología y Salud Pública (CIBERESP), 28029 Madrid, Spain.
University of Cantabria, 39005 Santander, Spain.

Hermann Brenner (H)

Division of Clinical Epidemiology and Aging Research, German Cancer Research Center (DKFZ), D-69120 Heidelberg, Germany.
German Cancer Consortium (DKTK), German Cancer Research Center (DKFZ), D-69120 Heidelberg, Germany.
Division of Preventive Oncology, German Cancer Research Center (DKFZ) and National Center for Tumor Diseases (NCT), Im Neuenheimer Feld 460, D-69120 Heidelberg, Germany.

Ben Schöttker (B)

Division of Clinical Epidemiology and Aging Research, German Cancer Research Center (DKFZ), D-69120 Heidelberg, Germany.

Jose Esteban Castelao (JE)

Genetic Oncology Unit, CHUVI Hospital, Complexo Hospitalario Universitario de Vigo, Instituto de Investigación Biomédica Galicia Sur (IISGS), 36204 Vigo, Spain.

Manuela Gago-Dominguez (M)

Genomic Medicine Group, Galician Foundation of Genomic Medicine, Instituto de Investigacion Sanitaria de Santiago de Compostela (IDIS), Complejo Hospitalario Universitariode Santiago, Servicio Galego de Saúde, SERGAS, 15706 Santiago de Compostela, Spain.
Department of Family Medicine and Public Health, Moores Cancer Center, University of California San Diego, La Jolla, CA 92037, USA.

Marija Gamulin (M)

Department of Oncology, University Hospital Centre Zagreb, 10 000 Zagreb, Croatia.
School of Medicine, University of Zagreb, 10 000 Zagreb, Croatia.

Davor Lessel (D)

Institute of Human Genetics, University Medical Center Hamburg-Eppendorf, D-20246 Hamburg, Germany.

Frank Claessens (F)

Molecular Endocrinology Laboratory, Department of Cellular and Molecular Medicine, Campus Gasthuisberg, University of Leuven, Herestraat 49, P.O. Box 901, 3000 Leuven, Belgium.

Steven Joniau (S)

Department of Urology, University Hospitals Leuven, Herestraat 49, P.O. Box 7003 41, 3000 Leuven, Belgium.
The Prostate Cancer Association Group to Investigate Cancer Associated Alterations in the Genome Consortium, Sutton SM2 5NG, UK.

Jong Y Park (JY)

Department of Cancer Epidemiology, Moffitt Cancer Center & Research Institute, Tampa, FL 33612, USA.

Classifications MeSH